Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed

Edwards Lifesciences Corp

2023-Q3 EPS reported $1.69 revenue$4,470,700,000

Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.
TAVR sales $961M (+11%); TMTT sales $52M on PASCAL Precision adoption; Surgical $247M (+12%).
Adjusted gross margin 76.4% vs 81.0% a year ago on FX headwinds; FY2023 guidance reaffirmed (10-13% CC sales growth, adj. EPS $2.50-$2.60).
Regulatory milestones: EVOQUE CE Mark (first transfemoral tricuspid replacement), PASCAL Precision approved in Japan, SAPIEN M3 pivotal trial enrollment completed.
Free cash flow $356M; $174M share repurchased in Q3; cash & short-term investments $1.9B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edwards Lifesciences Corp reported the quarter ended Sept. 30, 2023 results: revenue $1.48 billion, EPS $0.63. Guidance reaffirmed.

Period: the quarter ended Sept. 30, 2023
Revenue: $1.48 billion
EPS: $0.63
Guidance: reaffirmed
Result: reported results

Exact text from the filing

25, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook • Q3 sales grew 12 percent to $1.48 billion; constant currency 1 sales grew 11 percent • Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent • Q3 EPS of $0.63; adjusted 1 EPS of $0.59 • Received CE Mark

View on SEC.gov

Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.